A Randomized, Double Blind, Placebo and Active Controlled, Parallel, Multi-Center Phase IIb Study to Evaluate Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism

Trial Profile

A Randomized, Double Blind, Placebo and Active Controlled, Parallel, Multi-Center Phase IIb Study to Evaluate Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2014

At a glance

  • Drugs Enclomifene (Primary) ; Testosterone
  • Indications Hypogonadism
  • Focus Therapeutic Use
  • Sponsors Repros Therapeutics
  • Most Recent Events

    • 16 May 2013 The extension study was completed in January 2013, according to the ClinicalTrials.gov record.
    • 16 May 2013 The extension study was completed in January 2013, according to the ClinicalTrials.gov record.
    • 28 Dec 2011 It appears that patients enrolled in the extension study prefer to opt for enclomifene versus testosterone treatment, as reported in a Repros Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top